KRAS and neoplasm: Cancer immunotherapy that utilizes a peptide vaccine arising from epitopes of tumor-associated (TAA) or tumor-specific (TSA) neoantigens such as KRAS has the potential to modulate immune responses in a specific manner (Carbone et al., 2005; Toubaji et al., 2008; Rahma et al., 2014; Pan et al., 2019) [10,11,12,13].